Literature DB >> 31247224

Trends in therapeutic antibody affinity maturation: From in-vitro towards next-generation sequencing approaches.

Maryam Tabasinezhad1, Yeganeh Talebkhan2, Wolfgang Wenzel3, Hamzeh Rahimi4, Eskandar Omidinia5, Fereidoun Mahboudi6.   

Abstract

Current advances in antibody engineering driving the strongest growth area in biotherapeutic agents development. Affinity improvement that is mainly important for biological activity and clinical efficacy of therapeutic antibodies, has still remained a challenging task. In the human body, during a course of immune response affinity maturation increase antibody activity by several rounds of somatic hypermutation and clonal selection in the germinal center. The final outputs are antibodies representing higher affinity and specificity against a particular antigen. In the realm of biotechnology, exploring of mutations which improve antibody affinity while preserving its specificity and stability is an extremely time-consuming and laborious process. Recent advances in computational algorithms and DNA sequencing technologies help researchers to redesign antibody structure to achieve desired properties such as improved binding affinity. In this review, we briefly described the principle of affinity maturation and different corresponding in vitro techniques. Also, we recapitulated the most recent advancements in the field of antibody affinity maturation including computational approaches and next-generation sequencing (NGS).
Copyright © 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Affinity maturation; In silico; Mutagenesis; NGS

Mesh:

Substances:

Year:  2019        PMID: 31247224     DOI: 10.1016/j.imlet.2019.06.009

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  11 in total

1.  Structure and development of single domain antibodies as modules for therapeutics and diagnostics.

Authors:  Robert J Hoey; Hyeyoung Eom; James R Horn
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

2.  Targeting acute myeloid cell surface using a recombinant antibody isolated from whole-cell biopanning of a phage display human scFv antibody library.

Authors:  Thitima Sumphanapai; Kerry Chester; Surasak Sawatnatee; Jenny Yeung; Montarop Yamabhai
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 3.  Progress toward improved understanding of antibody maturation.

Authors:  Sandor Vajda; Kathryn A Porter; Dima Kozakov
Journal:  Curr Opin Struct Biol       Date:  2021-02-17       Impact factor: 6.809

4.  COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors.

Authors:  Anand Panchal; Pui Seto; Russell Wall; Brian J Hillier; Ying Zhu; Jessica Krakow; Aakash Datt; Elizabeth Pongo; Andisheh Bagheri; Tseng-Hui T Chen; Jeremiah D Degenhardt; Patricia A Culp; Danielle E Dettling; Maia V Vinogradova; Chad May; Robert B DuBridge
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

Review 5.  Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers.

Authors:  Kyusang Hwang; Jin Hwan Yoon; Ji Hyun Lee; Sukmook Lee
Journal:  Biomedicines       Date:  2021-01-05

6.  Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes.

Authors:  Halina Mikolajek; Miriam Weckener; Z Faidon Brotzakis; Jiandong Huo; Evmorfia V Dalietou; Audrey Le Bas; Pietro Sormanni; Peter J Harrison; Philip N Ward; Steven Truong; Lucile Moynie; Daniel K Clare; Maud Dumoux; Joshua Dormon; Chelsea Norman; Naveed Hussain; Vinod Vogirala; Raymond J Owens; Michele Vendruscolo; James H Naismith
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-15       Impact factor: 12.779

Review 7.  Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.

Authors:  Seung Hyun Kang; Chang-Han Lee
Journal:  Biotechnol Bioprocess Eng       Date:  2021-06-28       Impact factor: 2.836

Review 8.  Monoclonal antibody-based molecular imaging strategies and theranostic opportunities.

Authors:  Niels Dammes; Dan Peer
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 9.  Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.

Authors:  Ji Woong Kim; Yea Bin Cho; Sukmook Lee
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

10.  A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms.

Authors:  Yu-Jia Jin; Diao Yu; Xiao-Long Tian; Hui-Xian Li; Xiao-Chao Zhou; Yu Kong; Wei Zhang; Lu Zhang; Cheng Lei; Zhen-Lin Yang; Chao Tu; Yan-Ling Wu; Tian-Lei Ying
Journal:  Acta Pharmacol Sin       Date:  2021-07-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.